Viatris Revenue 2010-2024 | VTRS

Viatris annual/quarterly revenue history and growth rate from 2010 to 2024. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
  • Viatris revenue for the quarter ending December 31, 2024 was $3.528B, a 8.06% decline year-over-year.
  • Viatris revenue for the twelve months ending December 31, 2024 was $14.739B, a 4.46% decline year-over-year.
  • Viatris annual revenue for 2024 was $14.739B, a 4.46% decline from 2023.
  • Viatris annual revenue for 2023 was $15.427B, a 5.14% decline from 2022.
  • Viatris annual revenue for 2022 was $16.263B, a 9.08% decline from 2021.
Viatris Annual Revenue
(Millions of US $)
2024 $14,739
2023 $15,427
2022 $16,263
2021 $17,886
2020 $11,946
2019 $11,501
2018 $11,434
2017 $11,908
2016 $11,077
2015 $9,429
2014 $7,720
2013 $6,909
2012 $6,796
2011 $6,130
2010 $5,451
2009 $5,093
Viatris Quarterly Revenue
(Millions of US $)
2024-12-31 $3,528
2024-09-30 $3,751
2024-06-30 $3,797
2024-03-31 $3,663
2023-12-31 $3,837
2023-09-30 $3,942
2023-06-30 $3,919
2023-03-31 $3,729
2022-12-31 $3,876
2022-09-30 $4,078
2022-06-30 $4,117
2022-03-31 $4,192
2021-12-31 $4,342
2021-09-30 $4,537
2021-06-30 $4,578
2021-03-31 $4,430
2020-12-31 $3,624
2020-09-30 $2,972
2020-06-30 $2,731
2020-03-31 $2,619
2019-12-31 $3,192
2019-09-30 $2,962
2019-06-30 $2,852
2019-03-31 $2,496
2018-12-31 $3,079
2018-09-30 $2,862
2018-06-30 $2,808
2018-03-31 $2,685
2017-12-31 $3,239
2017-09-30 $2,987
2017-06-30 $2,962
2017-03-31 $2,720
2016-12-31 $3,268
2016-09-30 $3,057
2016-06-30 $2,561
2016-03-31 $2,191
2015-12-31 $2,491
2015-09-30 $2,695
2015-06-30 $2,372
2015-03-31 $1,872
2014-12-31 $2,083
2014-09-30 $2,084
2014-06-30 $1,837
2014-03-31 $1,716
2013-12-31 $1,809
2013-09-30 $1,767
2013-06-30 $1,702
2013-03-31 $1,632
2012-12-31 $1,723
2012-09-30 $1,802
2012-06-30 $1,688
2012-03-31 $1,584
2011-12-31 $1,531
2011-09-30 $1,576
2011-06-30 $1,574
2011-03-31 $1,449
2010-12-31 $1,434
2010-09-30 $1,355
2010-06-30 $1,369
2010-03-31 $1,292
2009-12-31 $1,352
2009-09-30 $1,264
2009-06-30 $1,267
2009-03-31 $1,210
Sector Industry Market Cap Revenue
Medical Medical Services $10.375B $14.739B
Viatris, Inc. is a global healthcare company. Its portfolio comprises more than thousand approved molecules across a wide range of key therapeutic areas, including globally recognized iconic and key brands, generic, complex generic, and biosimilar products. Branded products include EpiPen, Amitiza, Lipitor and Viagra. Biosimilars portfolio include pegfilgrastim, trastuzumab and adalimumab biosimilars. It has obtained approval for the biosimilar of Avastin and Insulin Aspart in Europe. The company reports in following segments: Developed Markets, Greater China, JANZ & Emerging Markets. The Developed Markets segment comprises operations in N. America and Europe. The Greater China segment operates in China, Taiwan and Hong Kong. The JANZ segment will report for operations in Japan, Australia and New Zealand, while the Emerging Markets segment will include operations in Asia, the Middle East, South and Central America, Africa and E. Europe. This segment also includes the company's anti-retroviral franchise.
Stock Name Country Market Cap PE Ratio
Danaher (DHR) United States $140.350B 26.32
Elevance Health (ELV) United States $91.117B 11.76
CVS Health (CVS) United States $79.102B 9.83
Cencora (COR) United States $56.251B 19.57
DiDi Global (DIDIY) China $21.979B 33.36
Natera (NTRA) United States $20.836B 0.00
BioMerieux (BMXMF) France $15.355B 0.00
Solventum (SOLV) United States $12.822B 13.57
EUROFINS SCIENT (ERFSF) Luxembourg $12.604B 0.00
CochLear (CHEOY) Australia $11.282B 0.00
Revvity (RVTY) United States $10.993B 18.92
ICON (ICLR) Ireland $10.630B 9.88
Doximity (DOCS) United States $9.813B 45.70
Avantor (AVTR) United States $9.138B 13.28
Medpace Holdings (MEDP) United States $8.785B 23.33
HealthEquity (HQY) United States $8.497B 41.80
Sonic Healthcare (SKHHY) Australia $8.220B 0.00
Charles River Laboratories (CRL) United States $6.924B 13.57
Amplifon S.p.A (AMFPF) Italy $4.966B 26.21
BrightSpring Health Services (BTSG) United States $4.257B 39.40
Bausch + Lomb (BLCO) Canada $4.156B 24.50
Sotera Health (SHC) United States $3.633B 20.65
Alignment Healthcare (ALHC) United States $3.122B 0.00
Surgery Partners (SGRY) United States $3.068B 39.90
Concentras Parent (CON) United States $2.912B 16.83
Organon (OGN) United States $2.350B 2.50
Ardent Health Partners (ARDT) United States $2.204B 9.40
GeneDx Holdings (WGS) United States $1.949B 75.07
Progyny (PGNY) United States $1.912B 42.08
Premier (PINC) United States $1.904B 14.45
PACS (PACS) United States $1.647B 0.00
GoodRx Holdings (GDRX) United States $1.414B 28.29
Teladoc Health (TDOC) United States $1.319B 0.00
Pediatrix Medical (MD) United States $1.283B 9.76
Establishment Labs Holdings (ESTA) $1.046B 0.00
Agilon Health (AGL) United States $1.014B 0.00
Ryman Healthcare (RYHTY) New Zealand $0.998B 0.00
CareDx (CDNA) United States $0.977B 15.25
Nutex Health (NUTX) United States $0.972B 14.69
AMN Healthcare Services Inc (AMN) United States $0.869B 8.13
QDM (QDMI) Hong Kong, SAR China $0.729B 0.00
Embecta (EMBC) United States $0.702B 4.73
InnovAge Holding (INNV) United States $0.566B 0.00
Enhabit (EHAB) United States $0.539B 44.33
Auna S.A (AUNA) Luxembourg $0.514B 13.63
Sonida Senior Living (SNDA) United States $0.494B 0.00
LifeMD (LFMD) United States $0.487B 0.00
COMPASS Pathways (CMPS) United Kingdom $0.370B 0.00
SBC Medicals (SBC) United States $0.352B 0.00
Oncology Institute (TOI) United States $0.226B 0.00
Beauty Health (SKIN) United States $0.218B 0.00
Performant Healthcare (PHLT) United States $0.209B 0.00
DocGo (DCGO) United States $0.150B 24.50
Sera Prognostics (SERA) United States $0.087B 0.00
So-Young (SY) China $0.084B 0.00
OncoCyte (OCX) United States $0.080B 0.00
KindlyMD (KDLY) United States $0.078B 0.00
Ascend Wellness Holdings (AAWH) United States $0.065B 0.00
NeueHealth (NEUE) United States $0.062B 0.00
IceCure Medical (ICCM) Israel $0.058B 0.00
Biodesix (BDSX) United States $0.044B 0.00
Basel Medical Group (BMGL) Singapore $0.044B 0.00
Pheton Holdings (PTHL) China $0.036B 0.00
NeuroOne Medical Technologies (NMTC) United States $0.033B 0.00
ModivCare (MODV) United States $0.013B 0.00
SeaStar Medical Holding (ICU) United States $0.013B 0.00
Co-Diagnostics (CODX) United States $0.010B 0.00
Intelligent Bio Solutions (INBS) United States $0.008B 0.00
BioNexus Gene Lab (BGLC) $0.005B 0.00
XWELL (XWEL) United States $0.005B 0.00
Aclarion (ACON) United States $0.004B 0.00
ISpecimen (ISPC) United States $0.003B 0.00
INVO Fertility (IVF) United States $0.002B 0.00
NewGenIvf Group (NIVF) Thailand $0.002B 0.00
Cano Health (CANOQ) United States $0.000B 0.00